Skip to content
HowShorted

Prestige Consumer Healthcare Inc. short interest in 2023

In 2023, Prestige Consumer Healthcare Inc.'s disclosed short interest ran from 2.19% of shares outstanding on 13 Jan 2023 to 3.23% on 29 Dec 2023, a change of +1.04 percentage points. The year's high was 3.23% on 29 Dec 2023 and its low 1.84% on 28 Feb 2023, averaging 2.67% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.33 days on 30 Nov 2023. Full history: Prestige Consumer Healthcare Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Prestige Consumer Healthcare Inc. in 2023

2023 in figures

Start of year
2.19% (13 Jan 2023)
End of year
3.23% (29 Dec 2023)
Change
+1.04 pp
High
3.23% (29 Dec 2023)
Low
1.84% (28 Feb 2023)
Average
2.67%
Highest days to cover
9.33 (30 Nov 2023)
SEC filings marked
8

Every report in 2023

Prestige Consumer Healthcare Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20232.19%4.25
31 Jan 20232.07%4.03
15 Feb 20231.91%3.3010-Q filed, results (8-K)
28 Feb 20231.84%3.59
15 Mar 20232.21%3.83
31 Mar 20232.27%3.26
14 Apr 20232.35%6.51
28 Apr 20232.29%6.82
15 May 20232.41%5.11results (8-K), 10-K filed
31 May 20232.62%5.67
15 Jun 20232.78%5.36
30 Jun 20232.57%4.56
14 Jul 20232.68%6.67
31 Jul 20232.88%6.26
15 Aug 20232.83%5.8610-Q filed, results (8-K)
31 Aug 20232.98%6.12
15 Sep 20233.08%5.36
29 Sep 20233.16%7.50
13 Oct 20233.05%7.30
31 Oct 20233.17%6.60
15 Nov 20233.22%7.4610-Q filed, results (8-K)
30 Nov 20233.13%9.33
15 Dec 20233.17%5.92
29 Dec 20233.23%7.07

See also: Prestige Consumer Healthcare Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.